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A B S T R A C T
Paravalvular leaks are common following valve replacement surgery. Majority are benign and do not
require any active intervention. However, occasionally severe paravalvular regurgitation can produce
heart failure and/or hemolysis, needing closure of the defect. It is more commonly associated with aortic
and mitral prosthesis, symptomatic tricuspid paravalvular regurgitation being a rare entity. In this report
we present the successful percutaneous transcatheter closure of a large paravalvular tricuspid
regurgitation in a 59-year old lady with history of multiple previous operations. The elongated crescent-
shaped defect was closed using two muscular VSD devices without any residual leak and without
hampering the bio-prosthetic tricuspid valve function. Patient had transient complete heart block during
the procedure which recovered later. There was marked improvement in the symptomatic status of the
patient at discharge (NYHA IV to NYHA II), which was sustained at follow-up.
 2016 Cardiological Society of India. Published by Elsevier B.V. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Paravalvular leaks (PVLL) are well known complications, both
early and late, after cardiac valve replacement surgeries. Varying
degrees of leaks can occur in up to 27% of cases.1 Although,
majority of the leaks are mild, larger defects can cause signiﬁcant
hemodynamic deterioration. In such situations, surgical re-
intervention is often necessary, but is associated with high
mortality and morbidity. In recent years, trans-catheter closure
of the paravalvular defects have become an effective alternative to
re-do surgery and is considered the favored approach in many
centers. Many devices are available now, but proper imaging of the
defect with accurate assessment of its size, shape and location, and
appropriate device selection forms the backbone of successful
intervention in these cases.
In this report we present a case of refractory heart failure due to
severe tricuspid PVLL, closed successfully using 2 muscular
Ventricular septal defect (VSD) occluders leading to remarkable
clinical and hemodynamic improvement.Abbreviations: PVLL, paravalvular leak; VSD, ventricular septal defect.
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Our patient, a 59 year old lady, underwent closed mitral
valvotomy for Rheumatic mitral stenosis at 24 years of age. 7 years
later she underwent mitral valve replacement with Starr Edwards
ball and cage mechanical valve for severe mitral re-stenosis.
Although not on any secondary prophylaxis, she remained fairly
well for nearly 3 decades, until recently, when she developed
progressive dyspnea along with features of right heart failure.
Subsequently, she underwent tricuspid valve replacement with
29 mm St. Jude Medical Biocor bioprosthetic valve for severe low
pressure tricuspid regurgitation. Because of transient heart block
during the surgery, epicardial right atrial (RA) and RV permanent
pacing leads were placed and left sheathed in the right sub-
pectoral pocket. At discharge, mild tricuspid PVLL was noted and
patient was advised follow up for the same.
In 6 months time our lady returned with symptoms of severe
congestive cardiac failure. There was no fever or any history
suggestive of recurrence of acute rheumatic fever. Clinical
examination revealed markedly elevated venous pressures with
prominent V waves, grossly pulsatile liver, pedal edema and
ascites. She was also in atrial ﬁbrillation with controlled
ventricular rate. Trans-thoracic as well as trans-esophageal
echocardiograms were performed which showed severe PVLL
through a large defect related to the antero-medial portion (septalosure of symptomatic large tricuspid paravalvular regurgitation
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Fig. 1. Transthoracic echocardiogram showing a large tricuspid paravalvular leak (4 chamber view); right atrium massively dilated due to signiﬁcant regurgitation.
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possible suture dehiscence. It was a crescentic defect measuring
approximately 12 mm in width and 24 mm in length. The
bioprosthetic valve function was normal. The RA was signiﬁcantly
dilated with mild RV dysfunction.
Since the patient had already undergone three previous cardiac
surgeries, a redo surgical repair was considered to be associated
with high risk (EUROSCORE II-4.89%). To complicate matters,
the lady was on high dose Warfarin (target INR: 3–3.5) for the
prosthetic mitral valve and recent onset atrial ﬁbrillation. The
other viable option was trans-catheter closure of the defect. The
pros and cons of each method were discussed in our multidisci-
plinary heart team meeting. The consensus decision was to do
percutaneous device closure.Fig. 2. RV angiogram (AP view) after deployment of the ﬁrst device shows
signiﬁcant residual leak (white arrows) in-spite of having a large sheath through the
defect.
Please cite this article in press as: Mukherji A, et al. Percutaneous cl
using two muscular VSD occluders, Indian Heart J. (2016), http://dxAccordingly, patient was taken up for device closure under
ﬂuoroscopic and transthoracic echocardiography guidance. Under
local anesthesia both right and left femoral venous accesses were
obtained (in view of possible need for multiple devices). RV
angiogram done at the beginning of the procedure showed severe
regurgitation across the paravalvular defect. However, the wide
regurgitant jet made it difﬁcult to measure the exact size of the
defect. The defect was crossed using 6Fr Pigtail catheter and then
exchanged for a 10Fr Amplatzer delivery sheath from the right
femoral vein access. A second 10Fr Amplatzer sheath was also
passed through the defect into the RV from the left femoral venous
access. A 16 mm Amplatzer muscular VSD occluder (St. Jude
Medical, St. Paul, Minnesota) was then deployed across the defect.Fig. 3. Two muscular VSD devices deployed interlocked with one another (LAO
caudal view); devices are seen on the medial aspect of the tricuspid valve ring (red
arrow). Ball and cage mitral prosthesis seen on the left (white arrow).
osure of symptomatic large tricuspid paravalvular regurgitation
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Fig. 4. Echocardiography showing stable position of both devices with no residual shunt.
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The residual jet measured about 10 mm (Fig. 2). Another 16 mm
Lifetech Cera muscular VSD occluder (Lifetech Scientiﬁc, Shenzhen,
China) was then deployed across the defect interlocking with the
previous device (Fig. 3). Echocardiography showed complete
abolition of the PVLL and no impediment of bio-prosthetic
tricuspid valve function (Fig. 4). Finally the two devices were
released one after another under ﬂuoroscopy.
During the procedure, after deployment of the ﬁrst device,
patient developed complete heart block. She was hemodynami-
cally stable with a low ventricular rate of 35/min. Atropine
injection was given twice and temporary pacing was attempted.
However, due to massively dilated RA, it was very difﬁcult to pass
the pacing lead into RV across the bio-prosthetic valve. Isoprotere-
nol infusion was started and gradually ventricular rate picked up to
55/min. The rest of the procedure was completed uneventfully.
Since the patient already had epicardial leads from the previous
surgery permanent pacemaker implantation (Medtronic VVI RELIA
RESRO1) was performed using the previously placed leads.
However, within 24 h she returned to her basal rhythm of atrial
ﬁbrillation with adequate heart rate of 70–80 per minute. At
3 months follow-up all the clinical signs of heart failure had
regressed and patient’s symptom status had improved from NYHA
class IV to class II.
3. Discussion
Despite major advances in prosthetic valve replacement
surgery, clinically signiﬁcant paravalvular leaks occur in up to
1–5% patients. Surgical re-interventions were the treatment of
choice for large defects till few years back. However, such re-do
surgeries are usually associated with high risk of perioperative
mortality (6–15%).2 In almost 50% patients the perioperative
period is marked by complications such as prolonged ventilation
(>48 h), renal failure, arrhythmia, pneumonia, re-exploration,
neurologic or gastro-intestinal events.
In the early 1990s, Hourihan et al. reported the ﬁrst successful
percutaneous closure of paravalvular defect in three patients of
aortic paravalvular regurgitation using the Rashkind-Cuaso double
umbrella device.3 Although a technically difﬁcult procedure,
multiple reports of transcatheter closure of PVLL are now available
with overall success rates of 60–80%. Majority of the reportsPlease cite this article in press as: Mukherji A, et al. Percutaneous cl
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sites of prosthetic valve implantation. A variety of devices have
been used. The choice of device depends on the size, shape, location
and complexity of the paravalvular defect. Precise knowledge of
the different device characteristics is also crucial in order to select
the most appropriate occluder to close a speciﬁc paravalvar leak.4
Till date, very few reports have been published on the use of
occluder devices for correcting tricuspid PVLL. Serdar et al.5
reported the closure of a large tricuspid PVLL using Amplatzer
atrial septal occluder while other reports mention use of Amplatzer
duct occluders. Although, no purpose-speciﬁc occluder is available
for closure, Amplatzer vascular plug III (AVP-III) offers potential
advantage because of its oval shape. In-spite of its bulky
conﬁguration, we chose a muscular VSD occluder because of the
large size of the defect. The crescentic shape necessitated the use of
two devices to cover the entire defect. The interlocked position of
the two devices with one another, helped to increase the stability
as well as to eliminate the residual shunt between them. The sizing
of the devices was based on echocardiographic measurement of
the defect size and angiographic ﬁndings. Intra-procedure balloon
sizing was avoided as it is technically difﬁcult for such elliptical
defects. Moreover, even highly compliant balloons can potentially
stretch the defect. To the best of our knowledge this is the ﬁrst time
two muscular VSD occluders have been used to successfully close
such a large tricuspid paravalvular defect.
Imaging modalities like 3-D TEE has revolutionized planning
and performance of various structural cardiac interventions, and
nowadays it is being used in almost all cases of paravalvular leak
closure.6 In our patient standard (2-D) TEE was done as a pre-
procedure work-up and the intervention was carried out with
transthoracic echocardiography guidance. Exact sizing of the
defect was important and it was ascertained by viewing the
defect in two orthogonal views. The excellent anatomic delineation
of the defect and surrounding structures provided by 3-D TEE
would offer advantages in difﬁcult cases. However it is not
mandatory for the procedure as evident in our case.
Owing to its anatomic location, tricuspid PVLL closure is
probably a technically easier procedure compared to mitral
paravalvular defect occlusion. However, as seen in our patient,
closure of defects on the antero-medial aspect of the tricuspid
prosthesis can be tricky due to proximity to the nodal tissue. As in
perimembranous VSD closure, the propensity for heart blockosure of symptomatic large tricuspid paravalvular regurgitation
doi.org/10.1016/j.ihj.2016.10.009
A. Mukherji et al. / Indian Heart Journal xxx (2016) xxx–xxx4
G Model
IHJ-1057; No. of Pages 4should always be taken into consideration while planning for
device in this area.
4. Conclusion
Percutaneous closure of paravalvular defects is a safe and
effective alternative to high risk re-do surgeries. Haemodynami-
cally signiﬁcant tricuspid PVLL can be corrected successfully using
muscular VSD occluders. Because of the large size and crescentic
shape of the defects, multiple devices may be often necessary to
achieve successful closure.
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